ClinicalTrials.govpublic full text
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
multiple myeloma, bcl-2 inhibitor, apg-2575, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 880781
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.